Bristol-Myers Squibb BMY Acquired IPRD
Acquired IPRD at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept bmy:AcquiredIPRD.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's acquired iprd.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's acquired IPRD?
- Bristol-Myers Squibb (BMY) reported acquired IPRD of $94M in Q1 2026.
- How has Bristol-Myers Squibb's acquired IPRD changed year-over-year?
- Bristol-Myers Squibb's acquired IPRD decreased by 50.0% year-over-year, from $188M to $94M.
- What is the long-term trend for Bristol-Myers Squibb's acquired IPRD?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's acquired IPRD has grown at a 33.9% compound annual growth rate (CAGR), from $1.16B to $3.72B.
- What does acquired IPRD mean?
- Costs associated with purchasing ongoing research projects from other companies.
- How do you interpret acquired IPRD?
- High levels indicate an active M&A strategy to acquire new drug candidates, often leading to future growth but immediate accounting charges.
- How does acquired IPRD compare across companies?
- Common in large-cap pharma companies that rely on inorganic growth.